Investigational Biologic for the Treatment of Migraine Shows Promise in Phase 3 Data

Thursday, November 17, 2016

New Phase 3 trial results suggest that Amgen’s investigational biologic agent erenumab may be effective at reducing migraines. Erenumab was specifically designed to prevent migraine by blocking the Calcitonin Gene-Related Peptide (CGRP) receptor, which is believed to have a critical role in mediating the incapacitating pain of migraine, according to Amgen. Patients enrolled in STRIVE study were randomized to receive either placebo, or one of two erenumab doses—70mg or 140mg—subcutaneously, once monthly for six months. At baseline, patients were experiencing an average of 8.3 migraine days per month. Patients in the erenumab 70mg and 140mg treatment arms experienced reductions of 3.2 and 3.7 days from baseline in monthly migraine days, respectively, as compared to a 1.8-day reduction in the placebo arm. The researchers noted that the safety profile for erenumab was comparable to placebo across both treatment arms and consistent with previous studies.

Next Story


You must be logged in to leave a comment.